Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor- bearing state

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 400-405

  Harada, Mamoru ^a   Tamada, Koji ^a   Abe, Koichiro ^a   Li, Tieli ^a   Onoe, Yasuhiro ^a   Tada, Hitoshi ^a   Takenoyama, Mitsuhiro ^b   Yasumoto, Kosei ^b   Kimura, Genki ^a   Nomoto, Kikuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; LUNG METASTASIS; LYMPH NODE CELL; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; LYMPH NODES; LYMPHOMA, T-CELL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION;

EID: 0032579548     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980130)75:3<400::AID-IJC13>3.0.CO;2-C     Document Type: Article

References (23)

1. BALCH, C.M., SOONG, S.J., MILTON, G.W., SHAW, H.M., MCGOVERN, V.J., MURAD, T.M., MCCARTHY, W.H. and MADDOX, W.A., A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama. USA. and New South Wales. Australia. Ann. Surg., 196, 677-684 (1982).
2. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY, M., WOLF, S.F., and GATELY, M.K., Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. exp. Med., 178, 1223-1230 (1993).
3. CHAN, S.H., PERUSSIA, B., GUPTA, J.W., KOBAYASHI, M., POSPISIL, M., YOUNG, H.A., WOLF, S.F., YOUNG, D., CLARK, S.C. and TRINCHIERI, G., Induction of interferon-γ production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J. exp. Med., 173, 869-879 (1991).
4. GATELY, M.K., DHSAI, B.B., WOLITZKY, A.G., QUINN, P.M., DWYER, C.M., PODLASKI, F.J., FAMILLETTI, P.C., SINIGAGLIA, F., CHIZONNITE, R., GUBLER, U. and STERN, A.S., Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147, 874-882 (1991).
5. HARADA, M., OKAMOTO, T., OMOTO, K., TAMADA, K., TAKENOYAMA, M., HIRASHIMA, C., ITO, O., KIMURA, G. and NOMOTO, K., Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies. Immunology, 87, 447-453 (1996).
6. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LOUDON, R., SHERMAN, F., PERUSSIA, B. and TRINCHIERI, G., Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. exp. Med., 170, 827-845 (1989).
7. MANETTI, R., PARRONCHI, P., GIUDIZI, M.G., PICCINNI, M.P., MAGGI, E., TRINCHIERI, G. and ROMAGNAI, S., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. exp. Med., 177, 1199-1204 (1993).
8. MILTON, G.W., SHOW, H.M., MCCARTHY, W.H., PEARSON, L., BALCH, C.M. and SOONG, S.J., Prophylactic lymph node dissection in clinical stage 1 cutaneous malignant melanomas: results of surgical treatment in 1319 patients. Brit. J. Surg., 69, 108-111 (1982).
9. MU, J., ZOU, J.P., YAMAMOTO, N., TSUTSUI, T., TAI, X.G., KOBAYASHI, M., HERMANN, S., FUJIWARA, H. and HAMAOKA, T., Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55, 4404-4408 (1995).
10. NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNIK, M.A., BRUNDA, M.J., GATELY, M.K., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J. and LOTZE, M.T., Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. j. Immunol., 153, 1697-1706 (1994).
11. OKAMOTO, T., HARADA, M., SHINOMIYA, Y., MATSUZAKI, G. and NOMOTO, K., The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatorysignal-providing cells. Cancer Immunol. Immunother., 40, 173-181 (1995).
12. OKAMOTO, T., HARADA, M., TAMADA, K., YOSHIDA, H., ITO, O., KONG, Y.Y., TAKENOYAMA, M., HIRASHIMA, C., MATSUZAKI, G. and NOMOTO, K., Local injection of OK432 can augment the Th1-type T-cell response in tumordraining lymph node cells and increase their immunotherapeutical potential. Int. J. Cancer, 70, 598-605 (1997).
13. + T lymphocytes and NK cells. J. Immunol., 149, 3495-3502 (1992).
14. ROBERTSON, M.J., SOIFFER, R.J., WOLF, S.F., MANLEY, T.J., DONAHUE, C., YOUNG, D., HERMANN, S.H. and RITZ, J., Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. exp. Med., 175, 779-788 (1992).
15. SIM, F.H., TAYLOR, W.F., PRITCHARD, D.J. and SOULÉ. E.H., Lymphadenectomy in management of stage I malignant melanoma: a prospective randomized study. Mayo Clin. Proc., 61, 697-705 (1986).
16. SUNGLUFF, JR., C.L., STIDHAM, K.R., RICCI, W.M., STANLEY, W.E. and SEIGLER, H.F., Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann. Surg., 219, 120-130 (1994).
17. STERN, A.S., PODIASKI, F.J., HULMES, J.D., PAN, Y.E., QUINN, P.M., WOLITZKY, A.G., FAMILLETTI, P.C., STERMLO, D.L., TRUITT, T., CHIZZONITE, R. and GATELY, M.K., Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. nat. Acad. Sci. (Wash.), 87, 6808-6812 (1990).
18. TANNENBAUM, C.S., WICKER, N., ARMSTRONG, D., TUBES, R., FINKE, J., BUKOWSKI, R.M. and HAMILTON, T.A., Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol., 156, 693-699 (1996).
19. TRINCHIERI, G., Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today, 14, 335-337 (1993).
20. VERONESI, U. and 20 OTHERS, Inefficacy of immediate node dissection in stage I melanoma of the limbs. N. Engl. J. Med., 297, 627-630 (1977).
21. YOSHISAWA, H., CHANG, A.E. and SHU, S., Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147, 729-737 (1991).
22. ZITVOGEL, L., TAHARA, H., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., NALESNIK, M.A. and LOTZE, M.T., Cancer immunotherapy of established tumor with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol., 155, 1393-1403 (1995).
23. ZOU, J.P., YAMAMOTO, N., FUJII, T., TAKENAKA, H., KOBAYASHI, M., HERMANN, S.H., WOLF, S.F., FUJIWARA, H. and HAMAOKA, T., Systemic administration of rIL-12 induces complete tumor repression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol., 7, 1135-1145 (1995).